Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Liver save search
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.005 0.5% 0.5% 120K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
BIVI | $0.5025 2.18% 2.13% 850K
|
Health Technology
|
| O: -4.57%
H: 1.5%
C: 0.0%
biv201 meeting liver disease association positive trial study
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ALGS | $0.8204 -0.39% -0.39% 640K
|
Health Technology
|
| O: 0.0%
H: 1.3%
C: -9.26%
alg-0001 meeting hepatitis liver alg-000184 positive treatment therapeutics results
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Published: 2023-06-30 (Crawled : 05:00) - globenewswire.com
GNFT | $3.4449 -6.4% 3.5K
|
Health Technology
|
| O: 0.0%
H: 0.99%
C: -12.59%
elative rare liver disease positive trial results
Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO, GlaxoSmithKline, Pfizer, Merck, Takeda, Genentech, Boehringer Ingelheim, DNAtrix, Celldex
Published: 2023-06-29 (Crawled : 21:00) - prnewswire.com
FUSN | $21.4 -0.09% -0.09% 270K
|
Health Technology
|
| O: 0.0%
H: 7.19%
C: 4.94%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: 0.95%
H: 2.6%
C: 0.95%
liver companies active cancer market
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
Published: 2023-06-22 (Crawled : 12:00) - precisionbiosciences.com
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 1.69%
H: 1.67%
C: -3.18%
arcus liver presentation positive international
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
CMMB | $0.67 0.02% 3.4K
|
Manufacturing
|
| O: 0.57%
H: 1.14%
C: -13.71%
liver positive fibrosis trial therapeutics nash
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: 1.58%
H: 1.03%
C: 0.0%
cirrhosis liver positive meeting therapeutics study
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
MDGL | $204.51 -6.35% -6.78% 580K
|
Health Technology
|
| O: 0.18%
H: 3.75%
C: 3.28%
treatment fibrosis liver trial positive nash
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Published: 2022-12-20 (Crawled : 12:20) - globenewswire.com
ALT | $7.095 -6.28% -6.69% 2.2M
|
Commercial Services
|
| O: -4.19%
H: 21.16%
C: 21.06%
liver disease topline trial positive results
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $204.51 -6.35% -6.78% 580K
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
treatment fibrosis liver topline trial positive nash
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: -1.41%
H: 8.56%
C: 3.59%
liver disease topline trial therapeutics positive
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: -1.85%
H: 6.28%
C: 2.52%
cirrhosis liver meeting therapeutics positive study phase 2b
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
| Email alert
Add to watchlist
treatment hepatitis liver presentation positive international phase 2b chronic hepatitis b
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
Published: 2022-06-22 (Crawled : 13:00) - biospace.com/
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 1.97%
H: 18.15%
C: 15.94%
liver therapeutics positive international
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2022-04-14 (Crawled : 15:00) - biospace.com/
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: 1.9%
H: 9.94%
C: 8.07%
cirrhosis liver therapeutics positive phase 2b
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
Published: 2022-03-15 (Crawled : 15:00) - eyenoviabio.com
EYEN | $0.5897 8.68% 7.99% 770K
|
Health Technology
|
| O: -0.75%
H: 3.78%
C: 2.27%
optejet eye pos ces technology liver cel solutions positive results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.